The use of EETs blocker or antagonists to enhance the efficacy of AT1 blocker to treat diabetic retinopathy.

Description:

The use of EETs Blocker or Antagonists to Enhance the Efficacy of AT1 blocker to Treat Diabetic Retinopathy

 

Application:  Diabetic Retinopathy (DR)

 

 

Advantages/Benefits:

•       This technology in combination with AT1 receptor blockade prevents and reduces DR

•       This technology can address the 33% of the U.S. population predicted to develop Diabetes by 2050 (most of those patients will develop DR)

•       This technology can be used in conjunction with an existing hypertension treatment

 

 

Abstract: Diabetic retinopathy is a serious sight threatening complication that results from long-term diabetes. It causes progressive damage to the retina and affects the retinal circulatory system. The global diabetic retinopathy market is valued at almost $6 billion USD.  Diabetic retinopathy treatment depends on the extremity of the condition and may require intraocular injections, anti-VEGF drugs, laser surgery or vitrectomy.  Increasing prevalence of diabetes and DR associated blindness will fuel market growth into 2022.

 

Technology Summary: Augusta University’s technology #2017-036 entitled, The use of EETs Blocker or Antagonists to Enhance the Efficacy of AT1 blocker to Treat Diabetic Retinopathy, enhances the clinical efficacy of RAS blockade by AT1 receptor blockade.  When used in conjunction with AT1 blockade, EET blockers have been shown to reduce DR progression, and even prevent it in some cases. 

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Carl Clark
Director Technology Transfer
Augusta University
caclark@augusta.edu
Inventors:
Mong-Heng Wang
Mohamed Al-Shabrawey
Keywords:
© 2019. All Rights Reserved. Powered by Inteum